Lasa Supergenerics Limited (LASA) — Secretarial Compliance | 30 May 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Lasa Supergenerics Limited submitted its Annual Secretarial Compliance Report for the financial year ending March 31, 2026, confirming adherence to SEBI regulations with three material non-compliances identified during the review period. The company failed to appoint a qualified Company Secretary as Compliance Officer for the quarter ending December 31, 2025, and missed filing requirements for shareholding patterns, shareholder complaints, and quarterly corporate governance reports for the quarter ended March 31, 2026, due to delayed bill payments. Remedial actions included appointing a new Company Secretary on December 16, 2025, and filing all pending reports by May 12, 2026. The report confirms no ongoing regulatory actions and compliance with all other statutory obligations.

📄 View Original Announcement (PDF)

About Lasa Supergenerics Limited (LASA)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹31.41 Cr ROE: -20.2% ROCE: -17.9%

View full LASA stock details →

📡 Get AI alerts when LASA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track LASA — Free

📊 More LASA filings

See all LASA filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when LASA files new disclosures

Track LASA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track LASA — Free

Free account · 2 AI queries/day